Ranking Human Protein Targets by Assayed Compounds
Author Information
Author(s): Southan Christopher, Boppana Kiran, Jagarlapudi Sarma ARP, Muresan Sorel
Primary Institution: AstraZeneca R&D Mölndal
Hypothesis
How can we rank human protein targets based on bioactivity data from drug discovery literature and patents?
Conclusion
The study provides a comprehensive ranking of human drug targets based on the number of compounds linked to them, revealing significant insights into the drug target landscape.
Supporting Evidence
- The study extracted data from over 27,000 documents to analyze compound-to-target relationships.
- 1,736 human proteins and 1,654 gene identifiers were linked to 1,671,951 compound records.
- The top-278 most actively pursued targets cover 90% of the compounds analyzed.
- Significant differences were found in target rankings based on molecular topology.
Takeaway
The researchers looked at a lot of studies to see which human proteins are most often tested with different drugs, helping us understand which proteins are important for medicine.
Methodology
The study involved extracting compound-to-target relationships from a large database of bioactivity data derived from patents and journal articles.
Potential Biases
There may be biases due to the selection of journals and patents, which could affect the comprehensiveness of the data.
Limitations
The study's limitations include potential biases in data extraction from selected journals and patents, and the inability to capture all available data.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website